Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Survey of treatment recommendations for elderly patients with glioblastoma.

Vaz Salgado MA, Torres J, Esteban J, Gutiérrez JA, Ley L, Carrato A.

Clin Transl Oncol. 2019 Dec 20. doi: 10.1007/s12094-019-02260-2. [Epub ahead of print]

PMID:
31863352
2.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
3.

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.

Biau J, Chautard E, De Schlichting E, Dupic G, Pereira B, Fogli A, Müller-Barthélémy M, Dalloz P, Khalil T, Dillies AF, Durando X, Godfraind C, Verrelle P.

Radiat Oncol. 2017 Dec 6;12(1):197. doi: 10.1186/s13014-017-0929-2.

4.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R.

Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.

PMID:
18082451
5.

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.

Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E, Lopes JM, Costa P, Damasceno M, Reis RM.

Oncol Rep. 2010 Jun;23(6):1655-62.

PMID:
20428822
6.

Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.

Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group.

J Neurooncol. 2016 May;128(1):157-162. doi: 10.1007/s11060-016-2093-1. Epub 2016 Mar 4. Erratum in: J Neurooncol. 2018 Jan;136(1):221-222.

PMID:
26943851
7.

Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus.

Palmer JD, Bhamidipati D, Mehta M, Williams NL, Dicker AP, Werner-Wasik M, Shi W.

J Neurooncol. 2018 Nov;140(2):421-426. doi: 10.1007/s11060-018-2969-3. Epub 2018 Aug 7.

PMID:
30088191
8.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
9.

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M.

Cancer. 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406.

10.

MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?

Yamashita S, Yokogami K, Matsumoto F, Saito K, Mizuguchi A, Ohta H, Takeshima H.

J Neurosurg. 2018 May 4;130(3):780-788. doi: 10.3171/2017.11.JNS171710.

PMID:
29726772
11.

Management of Elderly Patients with Glioblastoma.

Roth P, Gramatzki D, Weller M.

Curr Neurol Neurosci Rep. 2017 Apr;17(4):35. doi: 10.1007/s11910-017-0740-3. Review.

12.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

13.

Treatment options and outcomes for glioblastoma in the elderly patient.

Arvold ND, Reardon DA.

Clin Interv Aging. 2014 Feb 21;9:357-67. doi: 10.2147/CIA.S44259. eCollection 2014. Review.

14.

Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.

Zarnett OJ, Sahgal A, Gosio J, Perry J, Berger MS, Chang S, Das S.

JAMA Neurol. 2015 May;72(5):589-96. doi: 10.1001/jamaneurol.2014.3739. Review.

PMID:
25822375
15.

Glioblastoma in the elderly: initial management.

de Moraes FY, Laperriere N.

Chin Clin Oncol. 2017 Aug;6(4):39. doi: 10.21037/cco.2017.06.03. Review.

16.

Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).

Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.

J Neurooncol. 2015 Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30.

PMID:
26423801
17.

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.

Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.

18.
19.

Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.

Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F.

J Neurooncol. 2011 Apr;102(2):311-6. doi: 10.1007/s11060-010-0324-4. Epub 2010 Aug 5.

PMID:
20686820
20.

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.

Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M.

Neuro Oncol. 2010 Mar;12(3):283-8. doi: 10.1093/neuonc/nop050. Epub 2010 Feb 1.

Supplemental Content

Support Center